Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | BLM | P54132 | 2/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.58 |
| ▸ | ESR1 | P03372 | 2/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.58 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.58 |
| ▸ | GGT1 | P19440 | 1/20 | 0.58 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.58 |
| ▸ | CFD | P00746 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24074071 | 0.87 | ALDH1A1 (0.51) | ALDH1A1KDM4EHSD17B10HPGDUSP2 | |
| SCHEMBL5604181 | 0.87 | KDM4E (0.76) | ALDH1A1KDM4EHSD17B10HPGDUSP2 | |
| SCHEMBL31618292 | 0.86 | CFD (0.69) | ALDH1A1KDM4EHSD17B10HPGDUSP2 | |
| SCHEMBL138320 | 0.86 | CFD (0.69) | ALDH1A1KDM4EHSD17B10HPGDUSP2 | |
| SCHEMBL3800839 | 0.85 | ALDH1A1 (0.63) | ALDH1A1KDM4EHSD17B10HPGDUSP2 | |
| Aspirin SCHEMBL11791031 | 0.84 | KDM4E (0.65) | ALDH1A1KDM4EHSD17B10HPGDUSP2 | |
| SCHEMBL9949353 | 0.84 | ALDH1A1 (0.66) | ALDH1A1KDM4EHSD17B10HPGDUSP2 | |
| SCHEMBL15055753 | 0.83 | GAA (0.60) | ALDH1A1KDM4EHSD17B10HPGDUSP2 | |
| Methoxymethane SCHEMBL5317565 | 0.83 | CFD (0.65) | ALDH1A1KDM4EHSD17B10HPGDUSP2 | |
| SCHEMBL9318408 | 0.83 | ALDH1A1 (0.47) | ALDH1A1KDM4EHSD17B10HPGDUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060110743-A1 | Drug evolution: drug design at hot spots | KONISHI YASUO | 2006-05-25 | — | — | US | claimed |
| WO-2002095393-A2 | DRUG EVOLUTION: DRUG DESIGN AT HOT SPOTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2002-11-28 | — | — | WO | claimed |
| EP-0504560-A1 | Preparation of anhydride-capped polyphenylene ether in a melt process | GENERAL ELECTRIC COMPANY (US) | 1992-09-23 | — | — | EP | claimed |
| EP-0501154-A2 | Polyphenylene ether-polyamide compositions | GENERAL ELECTRIC COMPANY (US) | 1992-09-02 | — | — | EP | claimed |
| US-5141999-A | PREPARATION OF ANHYDRIDE-CAPPED POLYPHENYLENE ETHER IN A MELT PROCESS | GENERAL ELECTRIC COMPANY (US) | 1992-08-25 | — | — | US | claimed |
| US-5140077-A | Copolymers of an acetyl or phenyl 4-aminosalicylic acid trimellitamide-end capped polyphenylene ether and a polyamide as compatilizers for polyether/amide blends; heat and oxidation resistance | GENERAL ELECTRIC COMPANY (US) | 1992-08-18 | — | — | US | claimed |
| WO-2021239117-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI) , INC. (CN) | 2021-12-02 | — | — | WO | disclosed |
| US-20200237801-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES BASED ON BIOMARKER EXPRESSION | NOGRA PHARMA LIMITED (IE) | 2020-07-30 | — | — | US | disclosed |
| US-10473669-B2 | Methods for treating inflammatory bowel disease | NOGRA PHARMA LIMITED (IE) | 2019-11-12 | — | — | US | disclosed |
| US-20190112608-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES | CELGENE CORPORATION | 2019-04-18 | — | — | US | disclosed |
| EP-3355896-A2 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES BASED ON BIOMARKER EXPRESSION | Nogra Pharma Limited (IE) | 2018-08-08 | — | — | EP | disclosed |
| US-20180180630-A1 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | NOGRA PHARMA LIMITED (IE) | 2018-06-28 | — | — | US | disclosed |
| CN-107405413-A | Methods of using SMAD7 antisense oligonucleotides | 细胞基因阿尔派第二投资有限公司 | 2017-11-28 | — | — | CN | disclosed |
| CN-1970531-A | 4-azo salicylic acid derivative and process for producing the same and uses | UNIV SHANXI MEDICAL (CN) | 2007-05-30 | — | — | CN | disclosed |
| US-20060110743-A1 | Drug evolution: drug design at hot spots | KONISHI YASUO | 2006-05-25 | — | — | US | disclosed |
| WO-2002095393-A2 | DRUG EVOLUTION: DRUG DESIGN AT HOT SPOTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2002-11-28 | — | — | WO | disclosed |
| EP-0504560-A1 | Preparation of anhydride-capped polyphenylene ether in a melt process | GENERAL ELECTRIC COMPANY (US) | 1992-09-23 | — | — | EP | disclosed |
| EP-0501154-A2 | Polyphenylene ether-polyamide compositions | GENERAL ELECTRIC COMPANY (US) | 1992-09-02 | — | — | EP | disclosed |
| US-5141999-A | PREPARATION OF ANHYDRIDE-CAPPED POLYPHENYLENE ETHER IN A MELT PROCESS | GENERAL ELECTRIC COMPANY (US) | 1992-08-25 | — | — | US | disclosed |
| US-5140077-A | Copolymers of an acetyl or phenyl 4-aminosalicylic acid trimellitamide-end capped polyphenylene ether and a polyamide as compatilizers for polyether/amide blends; heat and oxidation resistance | GENERAL ELECTRIC COMPANY (US) | 1992-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112608-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES | SMAD3, SMAD2, SOST | ALDH1A1 4038/4885KDM4E 2900/4885HSD17B10 2970/4885 |
| US-20200237801-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES BASED ON BIOMARKER EXPRESSION | SMAD3, SMAD2, SOST | ALDH1A1 3968/4885KDM4E 3645/4885HSD17B10 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.